
Keywords: Asthma phenotypes; biologic therapies; eosinophils; IgE; IL-4; IL-5; IL-13; TH2/type 2 inflammation; ACQ; Asthma Control Questionnaire; DBPC; Double-blind, placebo-controlled; FDA; US Food and Drug Administration; Feno; Fraction of exhaled nitric oxide; I